RhinoSwab Adult Comfortable Self-Administered Nasal Swab

Rhinoswab is a patented comfortable, self-administered nasal swab that provides high-yield sampling and fits existing pathology workflows.

In response to the COVID-19 pandemic, Rhinomed applied its deep expertise in nasal airway technology to help address the global swab supply shortage. Through innovative modifications to our existing, proven nasal technology platform, we developed Rhinoswab – a comfortable, easy to use swab that opens up the potential for mass, population-wide sample self-collection. It was proven to be 100% accurate for the detection of SARS-COV-2 in spiking studies conducted by the Victorian Infectious Diseases Laboratory (VIDRL) when used in rt-PCR testing. Rhinoswab is registered as a Class 1 device in Europe (CE Mark), in the United States with the US Food and Drug Administration (FDA), and in Australia with the Therapeutic Goods Administration (TGA).

• Comfortable & Pain Free: Rhinoswab is comfortable to use addressing the problems with current nasopharyngeal swabs that are highly invasive and uncomfortable. 
• Self Administered: Rhinoswab is designed for self-collection in the home, at workplaces, clinical settings and anywhere that we need to test frequently and in large numbers.
• Dual Nostril Application For High Yield: The new Rhinoswab, with it’s dual swab heads has been shown to collect a 1.5 times larger sample than a traditional swab, offering the potential for a more effective diagnostic sample.
• Safer For Healthcare Workers: Easy self-collection with Rhinoswab reduces the risk to healthcare workers and the cost of personal protection equipment (PPE) required to protect them.
• Improved Standardization Of Collection: Less variability in collection technique may help reduce sampling & testing errors.
• Works With Both Laboratory And Poc Tests: Rhinoswab can be used for both rt-PCR and antigen tests, working seamlessly in laboratory and POC environments with standard vials and transport media.